Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 2 Sept 2008 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 2 Sept 2008 |
| Genmab to Attend 2nd Goldman Sachs Biotech Symposium | 1 Sept 2008 |
| Interim Report for the 6 months ended June 30, 2008 | 27 Aug 2008 |
| Genmab Announces 2008 First Half Year Results | 27 Aug 2008 |